HCPCS Level II code J1746 denotes the administration of ibalizumab-uiyk, 10 mg, a monoclonal antibody used in the treatment of certain multidrug-resistant HIV infections. This code identifies a specific biologic injection product and is relevant for clinicians, billing teams, specialty pharmacies, and payers managing claims for high-cost injectable therapies. Nationally, accurate use of J1746 is important for clinical documentation, inventory control, and appropriate payer adjudication for specialty infusions.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise breakdown of what the code represents, typical sites of service where the product is administered, and the operational billing considerations tied to a specialty biologic injection. The publication covers expected benchmarks and reimbursement context, common modifiers used with HCPCS Level II codes, and the clinical context for use of a monoclonal antibody infusion in HIV care.

The content is intended for a national audience of providers, coders, and payer analysts who need a clear reference for coding, billing, and documenting administration of this specialty injectable product. Data not available in the input is noted where applicable.